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Sean J. Morrison
Proneural basic helix–loop–helix transcription factors
such as Neurogenin are activators of neuronal gene
expression. Recent studies show they reinforce
neuronal differentiation by also inhibiting the
expression of glial genes, and are required in vivo to
prevent premature and excessive gliogenesis. 
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Do you ever wonder how it is possible to make a commit-
ment? For example, how do neural stem cells commit to
a neuronal fate, steadfastly avoiding the temptations of
gliogenesis? Our answer has been that stem cells express
master regulators of neuronal differentiation, the proneural
basic helix–loop–helix (bHLH) transcription factors, which
promote the expression of a cascade of other genes that
create neuronal identity [1]. The proneural bHLH genes
are necessary for the formation of many different types of
neuron in the central and peripheral nervous systems. But
is it enough for proneural genes to induce the expression
of neuronal genes, or must they also employ other mecha-
nisms to keep stem cells from seductive second thoughts
of gliogenesis? Recent studies [2–4] indicate that, in addi-
tion to promoting neuronal differentiation, proneural
bHLH transcription factors also act through independent
mechanisms to inhibit gliogenesis.
Proneural bHLH proteins regulate the onset and extent of
gliogenesis in vivo. Tomita and colleagues [2] studied mice
that were deficient for the proneural genes Mash1 and
Math3 and observed increased gliogenesis in the tectum,
hindbrain and retina, in addition to reduced neurogenesis.
Nieto and colleagues [3] studied mice that were deficient
for the proneural genes Mash1 and Neurogenin2 and observed
evidence of increased cortical gliogenesis in addition to
reduced neurogenesis. And now Sun and colleagues [4]
have provided a mechanism by which proneural bHLH
factors may regulate gliogenesis: Neurogenin1 inhibits gli-
ogenesis by binding the CBP/Smad1 or p300/Smad1 tran-
scriptional co-activator and sequestering it away from the
promoters of glial genes, preventing transcription.
These studies have two important implications for under-
standing how lineage determination occurs in stem cells.
Transcription factors that are important regulators of lineage
determination in the hematopoietic system consistently
inhibit alternative cell fates in addition to promoting
lineage-specific differentiation [5]. The demonstration that
proneural bHLH proteins inhibit gliogenesis suggests
that it may be a general strategy for lineage-determining
transcription factors to inhibit alternative cell fates while
acting as transcriptional activators to promote lineage-spe-
cific differentiation. These observations may also provide
insight into the mechanism behind the recent discovery
that Notch activation can promote glial lineage determina-
tion by neural stem cells [6–9]. As Notch inhibits the
expression of proneural bHLH genes, including Mash1 [6]
and Neurogenin [10], these recent papers suggest that
Notch may promote gliogenesis in stem cells by relieving
the inhibition imposed by proneural bHLH genes. 
What happens to cortical progenitors in the absence of
proneural bHLH transcription factors? Nieto et al. [3] ana-
lyzed mice that were deficient for Mash1 and/or Neuro-
genin2 and concluded that, in addition to reduced
neurogenesis, glial precursors are generated earlier and in
greater numbers in the double mutant mice. However,
only a minority of animals showed premature glial fibril-
lary acidic protein (GFAP) expression, suggesting that
loss of Mash1 and Neurogenin2 may accelerate glial
lineage determination but that other factors determine
the timing of overt differentiation. Tomita et al. [2]
observed accelerated gliogenesis in the tectum and hind-
brain, using both early and late glial markers, but not in
the retinas of Mash1/Math3-deficient mice. Thus gliogen-
esis is accelerated to different extents in different regions
of the nervous system, depending on which proneural
genes are deleted.
In vitro clonal analysis of cortical progenitors from
Neurogenin2 and/or Mash1 deficient mice suggests that
Mash1 deficiency has a greater effect than Neurogenin2
deficiency on glial lineage determination. Nieto et al.
[3] examined the relative frequencies of progenitors that
formed neuron-only, glial-only, or mixed — multipotent —
colonies. Neurogenin2-deficient progenitors do not differ
in the types of colony they form relative to wild-type cells,
suggesting that Mash-1 compensates for the lack of Neu-
rogenin2 in these mice. In Mash-1 deficient mice, the
Neurogenin2-expressing subset of progenitors also form
colonies similar to wild-type cells, but the subset of cells
that do not express Neurogenin2 exhibit a dramatic
increase in clones that make only glia. This suggests that
Mash-1 and Neurogenin2 can largely compensate for
each other, but that in the absence of both proneural
genes, at least one subset of cortical progenitors exhibits
increased gliogenesis.
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So what happens in double mutant mice? Mice deficient
for both Mash-1 and Neurogenin2 exhibit an increase in
mixed clones and a decrease in neuronal clones but no
change in clones containing only glia [3]. Given the appear-
ance of an increase in the number of immature glia in
double mutants in vivo, and the increased gliogenesis in
one subset of progenitors from the Mash-1-deficient mice,
this failure to observe increased glial commitment in the
double mutant is puzzling. One possible explanation is
that proneural genes are necessary to avoid premature glial
lineage determination, but loss of proneural genes is not
sufficient to cause glial commitment. Perhaps the progeni-
tors from double mutant mice are specified to undergo gli-
ogenesis but have not yet committed to the glial lineage,
so they form mixed colonies in culture but behave like
immature glia in vivo. Consistent with this hypothesis is
the observation that, unlike wild-type mixed clones, the
mixed clones from double mutant mice contain mainly glia
and very few neurons [3]. More data will be required to
understand the significance of these observations.
A complementary paper by Sun et al. [4] describes mecha-
nisms by which Neurogenin1 may inhibit glial lineage
determination by multipotent progenitors. Sun et al.
observed that Neurogenin1 strongly inhibits leukemia
inhibitory factor (LIF)-induced glial differentiation by cor-
tical progenitors in culture, even in cells that fail to undergo
overt neuronal differentiation. This suggests that Neuro-
genin1 may inhibit gliogenesis independently of its ability
to promote neuronal differentiation. Within the GFAP
promoter, the STAT — ‘signal transducer and activator
of transcription’ — transcription factor binding site is nec-
essary for the full Neurogenin1-mediated inhibition of
GFAP expression; Neurogenin1 binding sites are not nec-
essary. This suggests that inhibition does not require DNA
binding by Neurogenin1.
The STAT binding site promotes GFAP transcription by
binding a complex of STAT1/3, activated by LIF/ciliary
neurotrophic factor (CNTF) signaling, the ubiquitously
expressed transcriptional coactivators CBP or p300, and
Smad1, activated by bone morphogenetic protein (BMP)
signaling. Sun et al. [4] found that Neurogenin1 inhibits
the assembly of this complex by binding to both CBP and
Smad1, interfering with the ability of CBP/Smad1 to bind
STAT3 (see Figure 1). On top of this effect, Neurogenin1
also blocks LIF signaling by preventing STAT activation.
Thus, Neurogenin1 may inhibit glial lineage determina-
tion by sequestering the CBP/p300/Smad1 transcriptional
complex away from the promoters of glial genes, as well as
by suppressing STAT-mediated signal transduction.
In addition to implicating Neurogenin1 as an inhibitor of
gliogenesis, the work reported by Sun et al. [4] may also
explain why BMPs promote neurogenesis by stem cells in
some cases, while promoting gliogenesis in other cases. In
progenitors that express high levels of Neurogenin1, BMP
promotes neurogenesis, whereas in progenitors that express
low levels of Neurogenin1, BMP promotes gliogenesis.
This suggests that, in the presence of Neurogenin1, all the
endogenous CBP/p300/Smad1 is bound by Neurogenin
and diverted to neuronal promoters, preventing it from
interacting with STATs at glial promoters. In the absence
of Neurogenin1, CBP/p300/Smad1 is free to interact with
STATs to activate glial promoters.
Of course these interpretations require endogenous
CBP/p300 levels to be limiting. While Sun et al. [4] present
considerable evidence to support this model, it has not
yet been demonstrated that endogenous CBP/p300 levels
are limiting or that endogenous Neurogenin can bind to
all available CBP/p300. Nonetheless, the available data
suggest that Neurogenin1 is a molecular switch in stem
Figure 1
Neurogenin1 inhibits gliogenesis (red arrow pathway) by binding and
sequestering the CBP/p300/Smad1 transcriptional co-activator. In the
absence of Neurogenin1, the CBP/p300/Smad1 complex is recruited
to the promoters of glial genes by binding to activated STAT1/3. This
results in the expression of genes such as GFAP and glial
differentiation. When present, Neurogenin1 binds the
CBP/p300/Smad1 complex, recruiting it to the promoters of neuronal
genes (green arrow pathway), and sequestering it from the promoters
of glial genes. Neurogenin1 also inhibits the activation of STAT1/3. By
these two mechanisms, Neurogenin1 not only promotes the expression
of neuronal genes but inhibits the expression of glial genes. Consistent
with this model, bone morphogenetic proteins (blue arrow) promote
neurogenesis in the presence of Neurogenin1 and gliogenesis in the
absence of Neurogenin1. Notch activation may promote glial lineage
determination by inhibiting the expression of proneural bHLH genes,
such as Neurogenin, and perhaps through other proneural gene-
independent mechanisms. This figure was adapted from Sun et al. [4].
LIF-R, leukemia inhibitory factor receptor; BMP-R, bone morphogenetic
protein receptor; NeuroD, a neurogenic bHLH transcription factor,
downstream of Neurogenin1.
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cells that determines whether BMP signaling is gliogenic
or neurogenic.
The inhibition of gliogenesis by proneural bHLH genes
has implications for understanding how Notch activation
promotes gliogenesis in stem cells [6,9]. As Notch inhibits
the expression of proneural bHLH genes, Notch activa-
tion may inhibit neurogenesis and relieve the inhibition
of gliogenesis. But is this the whole story? Even transient
Notch activation accelerates glial lineage determination
in both neural crest stem cells [6] and central nervous
system stem cells [9]. Could simply inhibiting neurogene-
sis and relieving the inhibition of gliogenesis account for
irreversible and accelerated gliogenesis? Or must Notch
promote gliogenesis in additional ways that are indepen-
dent of its inhibition of proneural bHLH genes?
By analogy to other lineage determination factors, Notch
pathway genes might directly activate the transcription of
glial genes in addition to inhibiting alternative fates. Tani-
gaki et al. [9] found that constitutively active Notch is
capable of slightly promoting GFAP expression in the
absence of CNTF, and that this promotion does not
require STAT3 activation or even the STAT binding
site in the GFAP promoter. This suggests that the pro-
motion of gliogenesis by Notch does not depend on sig-
naling through the STAT pathway and is not entirely
based on  inhibiting the sequestration by Neurogenin of
CBP/p300/Smad1 from the STAT binding site [4]. Thus
Notch may promote gliogenesis in additional ways beyond
the inhibition of proneural gene expression. As all things
Notch related turn out to be unendingly complicated this
should not be surprising.
It seems that commitment is engendered by the impetus
to traverse one path, and the inability to access other
paths. Proneural genes drive neuronal differentiation of
stem cells while inhibiting glial differentiation. But any
relationship is complex, and many details remain to be
added to the picture sketched by the Greenberg, Guille-
mot and Kageyama laboratories [2–4]. Can Mash1 sequester
the CBP/p300/Smad1 transcriptional coactivator or inhibit
STAT activation just like Neurogenin1? Do other proneural
bHLH proteins have similar activities? Does Notch
promote gliogenesis by inhibiting proneural gene expres-
sion? Can Neurogenin2 or Mash1 play some positive role
regulating glial differentiation or reinforcing commitment
after glial lineage determination has occurred? This is a big
step forward, but more work will be required before we
really know how to make a commitment.
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